Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Shuanglian Li"'
Autor:
Jinhua Ma, Ting Gong, Tingting Luo, Shuanglian Li, Li Zhong, Xin Zhao, Chenghao Mei, Huaqin Bu, Zhenxing Jia, Xiaohu Kuang, Xiaoli Wang, Zhou Fu, Daiyin Tian
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Respiratory syncytial virus (RSV) is the primary cause of bronchiolitis-related hospitalizations among children under 5 years of age, with reinfection being common throughout life. Maternal vaccination has emerged as a promising strategy, delivering
Externí odkaz:
https://doaj.org/article/e18fb33c4ee940209d52425c3a2eb85a
Publikováno v:
Frontiers in Pediatrics, Vol 11 (2023)
BackgroundThis study aims to analyze the research hotspots, evolution, and developing trends in pediatric bronchiectasis over the past 20 years using bibliometric analysis and visualization tools to identify potential new research directions.MethodsP
Externí odkaz:
https://doaj.org/article/3399ca29dbb54998a4ad65ab2a30e452
ANRIL REGULATES RETINOBLASTOMA PROGRESSION VIA TARGETING AUTOPHAGY BY MIR-328-3P/TSC1/ULK SIGNALING.
Publikováno v:
Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists; 2024, Vol. 75 Issue 3, p228-235, 8p
Autor:
Pasi A. Jänne, Shuanglian Li, Shu Jin, Veronica Bunn, Jianchang Lin, Steven Zhang, Sylvie Vincent, Danny Nguyen, Ryan D. Gentzler, Tarek Mekhail, Howard L. West, Viola W. Zhu, Lyudmila Bazhenova, Shirish M. Gadgeel, Jyoti D. Patel, Anne S. Tsao, Daniel B. Costa, Zofia Piotrowska, Alexander I. Spira, D. Ross Camidge, Joel W. Neal, Gregory J. Riely
Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR gene mutations, including exon 20 insertions (EGFRex20ins), in non–small cell lung cancer, was evaluated in a phase I/II dose-escalation/expansion trial (Clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31d2bc425d2ed40de9a8898b8fdcd6d6
https://doi.org/10.1158/2159-8290.c.6549404
https://doi.org/10.1158/2159-8290.c.6549404
Autor:
Kathleen M. Giacomini, David M. Jablons, Zhidong Xu, Ligong Chen, Sook Wah Yee, Shuanglian Li, Swati S. More
Picoplatin, a third-generation platinum agent, is efficacious against lung cancers that are otherwise resistant or become refractory during platinum treatment. This effort was aimed at the determination of the influence of organic cation transporters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf799c78f4dcc9ba8e808631dee99f74
https://doi.org/10.1158/1535-7163.c.6531783
https://doi.org/10.1158/1535-7163.c.6531783
Autor:
Steven Zhang, Daniel B. Costa, Gregory J. Riely, Viola W. Zhu, Howard West, Shuanglian Li, Pasi A. Jänne, Alexander I. Spira, Tarek Mekhail, Sylvie Vincent, Joel W. Neal, Jyoti D. Patel, Lyudmila Bazhenova, Shirish M. Gadgeel, Zofia Piotrowska, Veronica Bunn, D. Ross Camidge, Jianchang Lin, S. Jin, Anne S. Tsao, Ryan D. Gentzler, Danny Nguyen
Publikováno v:
Cancer Discovery. 11:1688-1699
Mobocertinib, an oral epidermal growth factor receptor (EGFR) inhibitor targeting EGFR gene mutations, including exon 20 insertions (EGFRex20ins), in non–small cell lung cancer, was evaluated in a phase I/II dose-escalation/expansion trial (Clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1424dccde96535f9934857a18f812ddd
https://doi.org/10.1158/2159-8290.cd-20-1598
https://doi.org/10.1158/2159-8290.cd-20-1598
Autor:
Chunhua Wen, Wenzhou Xiao, Ye Liu, Dick Jeffrey, Xiaohang Yu, Chaoyun Liu, Rijun Du, Shuanglian Li, Jianqing Lai
Publikováno v:
Acta Geologica Sinica - English Edition. 93:874-900
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f909cd79c4de20a60fd1365552b9fdf
https://doi.org/10.1111/1755-6724.13864
https://doi.org/10.1111/1755-6724.13864
Autor:
Huamao M. Lin, Rachel H. Bhak, Hui Huang, Mei Sheng Duh, Aaron Galaznik, Shuanglian Li, Thomas Kulalert, Maral DerSarkissian, Iryna Bocharova
Publikováno v:
Journal of the National Comprehensive Cancer Network. 17:HSR19-084
Background: Mutations in the epidermal growth factor receptor (EGFR) gene have been identified in 10%–50% of patients with non-small cell lung cancer (NSCLC). Exon 20 insertion mutations represent about 2%–10% of this group. Reports of real world
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78b51de28533a247100abf91fe19bea5
https://doi.org/10.6004/jnccn.2018.7200
https://doi.org/10.6004/jnccn.2018.7200
Autor:
Shan Ashton Garib, Anna Forsythe, Dimitrios Tomaras, Hui Huang, Aaron Galaznik, Shuanglian Li, Victoria Crossland, Huamao M. Lin
Publikováno v:
Journal of the National Comprehensive Cancer Network. 17:HSR19-082
Background: Epidermal growth factor receptor (EGFR) mutations are frequently found in non-small cell lung cancer (NSCLC) patients. Various EGFR mutations respond differently to EGFR tyrosine kinase inhibitors (TKIs), and several TKIs have been approv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54daa1298d8d7752d486ae20333a3ed8
https://doi.org/10.6004/jnccn.2018.7199
https://doi.org/10.6004/jnccn.2018.7199
Publikováno v:
IUBMB lifeREFERENCES. 72(9)
Retinopathy of prematurity is a major cause of childhood blindness worldwide. Hence, exploring the proper treatment methods is a must in tacking this disease. qRT-PCR and western blot were used to detect the expression of genes and proteins, respecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea712c0c0bdd991dbbce4a11796bec35
https://pubmed.ncbi.nlm.nih.gov/32584521
https://pubmed.ncbi.nlm.nih.gov/32584521